All In Biotech

Drug Trial Radar · NCT03886688

HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers

A Phase 1, Double-blind, Randomized, Placebo-controlled, Dose-escalation, Pharmacokinetic Study of Single and Multiple Oral Dosing of HEC53856, A Novel HIF-PHD Inhibitor, in Healthy Non-elderly Volunteers.

Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

May 14, 2019

Primary completion

Jan 1, 2020

Study completion Jan 1, 2020

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability and pharmacokinetics of HEC53856 after single or multiple oral administration, as well as the food effect on the pharmacokinetics, in healthy non-elderly subjects.

Conditions

  • Healthy

Interventions

  • HEC53856Drug

    oral administration

  • placeboDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events [Safety and Tolerability]Time frame: Up to Day 10 after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.